Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense

Inclusion Criteria: * Male or female patient * 15 years of age or older * Signed informed consent form (as well as assent from illiterate and under-age patients, and those unable to give consent) * Karnofsky Performance Status above 50 * Able to ingest oral tablets * Having a permanent address or being traceable by other persons * Able to comply with the schedule of follow-up visits and requirements of the study * Agreement to be hospitalised in order to receive treatment * For patients with late-stage HAT: * Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph and/or the CSF, at the investigational centre * If trypanosomes are found in the blood or lymph, but not in the CSF, the CSF WBC, measured at the investigational centre, must be above 20/μL for the patient to be included in the cohort of patients with late-stage HAT * For patients with early- or intermediate-stage HAT: * Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph, at the investigational centre * Absence of parasites in the CSF * The CSF WBC, measured at the investigational centre, must be between 6 and 20/μL for the patient to be included in the cohort of patients with intermediate-stage HAT and equal to or below 5/μL for the patient to be included in the cohort of patients with early-stage HAT. Exclusion Criteria: * Severe malnourishment, defined as body-mass index (BMI) below 16 * Pregnancy or breastfeeding (for women of child-bearing po…